EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Physiologically Based Biopharmaceutics Modeling (PBBM): Best Practices for Drug Product Quality, Regulatory and Industry Perspectives: 2023 Workshop Summary Report

Claire Mackie iD, Sumit Arora iD, Paul Seo, Rebecca Moody, Bhagwant Rege, Xavier Pepin iD, Tycho Heimbach, Christer Tannergren iD, Amitava Mitra, Sandra Suarez-Sharp, Luiza Novaes Borges, Shinichi Kijima und 5 weitere

Molecular Pharmaceutics · 2024

DOI: 10.1021/acs.molpharmaceut.4c00202 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecular Pharmaceutics, 2024. Verfasst von Claire Mackie und 16 weiteren Autor:innen. Beteiligte Einrichtung: Janssen Pharmaceutica NV, Turnhoutseweg 30, Beerse 2340, Belgium. Hauptthemen laut MEDLINE: Biopharmaceutics, Drug Industry. Die Arbeit wurde bisher 72-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: FDA HHS, U.S. Food and Drug Administration.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Physiologically based biopharmaceutics modeling (PBBM) is used to elevate drug product quality by providing a more accurate and holistic understanding of how drugs interact with the human body. These models are based on the integration of physiological, pharmacological, and pharmaceutical data to simulate and predict drug behavior in vivo. Effective utilization of PBBM requires a consistent approach to model development, verification, validation, and application. Currently, only one country has a draft guidance document for PBBM, whereas other major regulatory authorities have had limited experience with the review of PBBM. To address this gap, industry submitted confidential PBBM case studies to be reviewed by the regulatory agencies; software companies committed to training. PBBM cases were independently and collaboratively discussed by regulators, and academic colleagues participated in some of the discussions. Successful bioequivalence "safe space" industry case examples are also presented. Overall, six regulatory agencies were involved in the case study exercises, including ANVISA, FDA, Health Canada, MHRA, PMDA, and EMA (experts from Belgium, Germany, Norway, Portugal, Spain, and Sweden), and we believe this is the first time such a collaboration has taken place. The outcomes were presented at this workshop, together with a participant survey on the utility and experience with PBBM submissions, to discuss the best scientific practices for developing, validating, and applying PBBMs. The PBBM case studies enabled industry to receive constructive feedback from global regulators and highlighted clear direction for future PBBM submissions for regulatory consideration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BiopharmaceuticsDrug IndustryHumansModels, BiologicalTherapeutic EquivalencyPharmaceutical PreparationsUnited States

Stichwörter der Autor:innen

MIDD (model informed drug development)PBBM (physiologically based biopharmaceutics model(s)(ing)PBPK (physiologically based pharmacokinetics)biopredictive dissolutionclinically relevant dissolution specifications (CRDS)drug product performancedrug product qualitypatient-centric drug product quality standardssafe spacevirtual bioequivalence (VBE)

Substanzen

Pharmaceutical Preparations

Autor:innen und Institutionen

  • Janssen Pharmaceutica NV, Turnhoutseweg 30, Beerse 2340, Belgium.
  • Office of Translational Science, Office of Clinical Pharmacology (OCP), Center for Drug Evaluation and Research, Food and Drug Administration (FDA), 10903 New Hampshire Avenue, Silver Spring, Maryland 20993, United Stat…
  • Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland 20993, United States.
  • Regulatory Affairs, Simulations Plus, Inc., Lancaster, California 93534-7059, United States.
  • Pharmaceutical Sciences and Clinical Supply, Merck & Co., Inc., 123 East Scott Ave., Rahway, New Jersey 07065, United States.
  • Biopharmaceutics Science, New Modalities & Parenteral Product Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Gothenburg 431 83, Sweden.

ORCID-Profile: Claire Mackie, Sumit Arora, Xavier Pepin, Christer Tannergren, Maria Malamatari, James E Polli

Förderung

  • FDA HHS
  • U.S. Food and Drug Administration

Zitieren

APA

Mackie, C., Arora, S., Seo, P., Moody, R., Rege, B., Pepin, X., Heimbach, T., Tannergren, C., Mitra, A., Suarez-Sharp, S., Borges, L. N., Kijima, S., Kotzagiorgis, E., Malamatari, M., Veerasingham, S., Polli, J. E., & Rullo, G. (2024). Physiologically Based Biopharmaceutics Modeling (PBBM): Best Practices for Drug Product Quality, Regulatory and Industry Perspectives: 2023 Workshop Summary Report. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.4c00202

Vancouver

Mackie C, Arora S, Seo P, Moody R, Rege B, Pepin X, et al. Physiologically Based Biopharmaceutics Modeling (PBBM): Best Practices for Drug Product Quality, Regulatory and Industry Perspectives: 2023 Workshop Summary Report. Molecular Pharmaceutics. 2024. doi:10.1021/acs.molpharmaceut.4c00202

BibTeX
@article{Mackie2024,
  author = {Mackie, Claire and Arora, Sumit and Seo, Paul and Moody, Rebecca and Rege, Bhagwant and Pepin, Xavier and Heimbach, Tycho and Tannergren, Christer and Mitra, Amitava and Suarez-Sharp, Sandra and Borges, Luiza Novaes and Kijima, Shinichi and Kotzagiorgis, Evangelos and Malamatari, Maria and Veerasingham, Shereeni and Polli, James E and Rullo, Gregory},
  title = {Physiologically Based Biopharmaceutics Modeling (PBBM): Best Practices for Drug Product Quality, Regulatory and Industry Perspectives: 2023 Workshop Summary Report},
  journal = {Molecular Pharmaceutics},
  year = {2024},
  doi = {10.1021/acs.molpharmaceut.4c00202}
}
Kostenlos starten →